Editas Q2 net loss $40.3M ($0.56/sh); cash $480M; EDIT-301 on track for 20 patients by year-end

Editas Medicine, Inc.

2023-Q2 EPS reported -$1.27 revenue$12,738,000

Net loss $40.3M ($0.56 per share) vs. $53.5M ($0.78) in Q2 2022.
Cash, cash equivalents and marketable securities $480.0M as of June 30, 2023.
EDIT-301 RUBY trial (SCD) on track to dose 20 total patients; clinical update by year-end.
EDIT-301 EDITHAL trial (TDT) commenced parallel dosing; update expected by year-end.
Erick Lucera appointed CFO and Linda C. Burkly, Ph.D. appointed CSO.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Editas Medicine, Inc. reported second quarter 2023 results: net income $40.3 million, EPS $0.56 per share.

Period: second quarter 2023
Net income: $40.3 million
EPS: $0.56 per share
Result: reported results

Exact text from the filing

For the three months ended June 30, 2023, net loss attributable to common stockholders was $40.3 million, or $0.56 per share, compared to net loss of $53.5 million, or $0.78 per share, for the same period in 2022.

View on SEC.gov

Browse all earnings releases →

Editas Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-012810

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.